Cancer is one of the deadliest diseases known to man, and according to statistics, over 40% of the human population would be diagnosed with cancer in their lifetimes. Scientists from around the world are working 24/7 to find a cure for the disease, and they are using all of their resources to do some research about how cancer can be stopped. One of these companies is Seattle Genetics, headed by Clay Siegall. Seattle Genetics was once a small startup company, but they managed to contribute so much in the field of oncology. Since the company’s establishment, Clay Siegall dedicated most of his time to researching cancer. He has been working with some of the best scientists around the world to create a drug that can cause possible treat cancer. Seattle Genetics has already introduced several medicines that can be used to slow down the development of the disease, and in some patients, the cancer cells die out.
The research conducted by Clay Siegall is focused on the development of new drugs that can treat cancer, and because of his dedication, he was named as one of the innovative leaders in the industry. Seattle Genetics managed to develop an antibody drug conjugates or ADCs for short, and he demonstrated how it could improve the status of a cancer patient. He further highlighted that ADCs are one of the essential components in the emerging market of cancer treatment development. He cleared out that ADCs might have a clue on how to combat the disease that has taken millions of lives.
With the new knowledge about ADCs, Clay Siegall decided to put it to the test. He created a drug that has been integrated with ADCs, and the result is a drug that can treat Hodgkin’s lymphoma. This cancer targets the body’s immune system, and it also targets the white blood cells. Most of the victims of the disease are young people, and with the discovery of the drug, Clay Siegall immediately introduced it to the public and named it Adcetris. The drug is now being shipped around the world, and most of the recipients who are suffering from Hodgkin’s lymphoma are reporting that they are feeling better after taking up the medicine.